Blue Sky Research Grant Recipients

Funded Blue Sky project: Precision medicine in MYC-driven tumours: a new predictive biomarker for topoisomerase-based therapy.

Funded Blue Sky project: Hi-live: profiling chromatin dynamics genome wide in single cells in real time.

Funded Blue Sky project: A new paradigm for large-scale genome-wide identification of driver mutations in melanoma patient samples by allele-specific footprinting.

Funded Blue Sky project: Oligonucleotide-based therapy for targeting DNA repair in hematological malignancies.

Funded Blue Sky project: Turning cold tumor to hot tumor using small molecule inhibitor for immunotherapy.

Funded Blue Sky project: Definition of a Mitochondrial Protein Complex to Target Mitochondrial Integrity in Cancer.

Funded Blue Sky project: Cracking the code: Utilization of naturally occurring mutations to augment the in vivo persistence of NK cells and thereby unleash their full therapeutic potential.

Funded Blue Sky project: Identifying fitness-enhancing gene programs in heterogeneous tumors.

Funded Blye Sky project: Is Pol III a novel player in cancer genome organization?

Funded Blue Sky project: Engineering synthetic particles as immunotherapy agents.

Funded Blue Sky project: How may Mechanotransduction Prevent Cancer?

Funded Blue Sky project: Deciphering mechanisms regulating the promalignant niche in pediatric brain tumors.

Funded Blue Sky Project: "Targeting chromatin spatial dis-organization in cancer"

Funded Blue Sky Project: "Improved Cancer Diagnosis with Multimodal 3D Imaging"

Funded Blue Sky Project: "Targeting fat cells to reduce breast cancer progression and metastasis in humans"

Funded Blue Sky Project: "Targeting MYC disorder with spider silk"

Funded Blue Sky Project: "In search of a strategy to sustainably restore hematopoietic niche in leukemia"

Funded Blue Sky Continuation Project: "How cells start DNA replication: mechanisms and therapeutic potential"

Bennie Lemmens is active at the Department of Medical Biochemistry and Biophysics (MBB) and the project is entitled "How Cells Start DNA Replication: Mechanisms and Therapeutic Potential". Co-applicant Jiri Bartek, MBB.

Mattias Rantalainen is active at the Department of Medical Epidemiology and Biostatistics (MEB) and the project is entitled "Predicting molecular phenotypes from histopathology images". Co-applicant Johan Hartman, Onk-Pat.

Nicholas Valerie is active at the Department of Oncology-Pathology (Onk-Pat) and the project is entitled "Rational design of AML-targeted CHD4 PROTACs for cancer therapy".

Lisa S. Westerberg is active at the Department of Microbiology, Tumor and Cell Biology (MTC) and the project is entitled "Driving antigen presentation in dendritic cells for tumor therapy".

Päivi Östling is active at SciLifeLab & the Department of Oncology-Pathology (Onk-Pat) and the project is entitled "Phenotypic high throughput drug screening to target cancers with defective nucleo-cytoskeletal architecture".

Igor Adameyko is active at the Department of Physiology and Pharmacology and the project is entitled “Prediction of new treatments for paraganglioma and pheochromocytoma based on single cell transcriptomics”

Katja Petzold is active at the Department of Medical Biochemistry and Biophysics and the project is entitled "How microRNA selects its targets".

Bertrand Joseph is active at the Department of Oncology-Pathology and the project is entitled "Cellular Reprogramming in Glioma Tumors."

Stephen Strom is active at the Department of Laboratory Medicine and the project is entitled "Humanized Models of Liver Cancer".

Jonas Fuxe is active at the Department of Medical Biochemistry and Biophysics and the project is entitled "Long-distance impact of inflammation on tumor cell invasion and metastasis."